ASCO 2013 - Poster: Open-label, multicenter study of sipuleucel-T in men with metastatic castrate resistant prostate cancer (mCRPC) previously treated with sipuleucel-T: Evaluation of antigen presenting cell (APC) activation and ELISPOT data

CHICAGO, IL USA (UroToday.com) - Presented by Beer TM,1 Glode LM,2 Lance RS,3 Greengold RH,4 Sims R,5 Wang Y,5 Sheikh N,5 and Corman JM6 at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

asco 2013 beers Open-label multicenter study of sipuleucel-T thumb

1Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA; 2University of Colorado Cancer Center, Aurora, CO, USA; 3Eastern Virginia Medical School, Norfolk, VA, USA; 4South Orange County Medical Research Center, Laguna Hills, CA, USA; 5Dendreon Corporation, Seattle, WA, USA; 6Virginia Mason Medical Center, Seattle, WA, USA


Click HERE to listen to a podcast by Tomasz M. Beer, MD, FACS, one of the participants in this study

The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making it an excellent venue for exploring the theme of the Meeting — "Building Bridges to Conquer Cancer."


asco x

View Full ASCO 2013 Coverage

 

 

 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe